anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/US96/20777 Sec. 371 Date Apr. 15, 1997 Sec. 102(e) Date Apr. 15, 1997 PCT Filed Dec. 13, 1996 PCT Pub. No. WO97/21825 PCT Pub. Date Jun. 19, 1997This invention provides a method for obtaining a recombinant retroviral packaging cell capable of producing retroviral vectors as well as the recombinant packaging cell obtained by the method. Also provided is a method of producing recombinant retroviral particles obtained by introducing into the packaging cells obtained according to the methods disclosed herein, a recombinant retroviral vector and propagating the resulting producer cells under conditions favorable for the production and secretion of retroviral vector supernatant. The retroviral supernatant produced by these methods also is claimed herein. This invention further provides a method for screening retroviral vector supernatant for high transduction efficiency and methods for producing retroviral vector supernatant for transducing cells with high efficiency in gene therapy applications.
The invention discloses a medicine for treating traumatic synovitis of knee joints and a preparation method thereof, and relates to an over-the-counter medicine for treating joint diseases of limbs. Is prepared from 7 Chinese-medicinal materials including impatiens balsamina, red sage root, Chinese angelica root, etc through immersing them in edible spirit brewed at 52-60 deg. C, removing dregs, and applying it on the affected part. The traditional Chinese medicine has mild medicine property, can expel wind and relieve pain, promote blood circulation and reduce swelling, and has quick response and short treatment course. Traumatic synovitis is caused by local sprain, external force injury, chronic strain and other meridian injury, unsmooth blood circulation, local stagnation, malnutrition of muscles and tendons, and invasion of wind-cold-dampness-heat evil in a deficient way, so that the obstruction of the veins is aggravated. The medicine is used for assisting the oral medicine in dissipating blood stasis, promoting tissue regeneration, relieving swelling and alleviating pain in the acute stage of synovitis; in the chronic stage, the medicine can dispel wind and dry dampness, and strengthen muscles and bones. The traditional Chinese medicine composition is frequently applied to patients to avoid repeated onset of synovitis and restore normal functions of joints, and solves the problem that no specific external medicine is available for treating knee joint traumatic synovitis at present. The product also has significant curative effects on rheumatic arthritis, tenosynovitis of fingers, traumatic injury and the like.
Patients receive tucatinib PO BID, trastuzumab IV over 30-90 minutes on days 1 and 15, and TAS-102 PO BID on days 1-5 and 8-12. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention discloses application of substances for synthesizing epoxidized polyunsaturated fatty acid and metabolic pathway in preparation of myocardial infarction drugs. The invention provides application of epoxidized polyunsaturated fatty acid in preparation of a medicament for treating myocardial infarction. The invention also provides application of a substance for synthesizing the epoxidized polyunsaturated fatty acid in the metabolic pathway in preparing a medicament for treating myocardial infarction. The invention also protects the application of the movement up-regulating factor in preparing the medicine with the indication of myocardial infarction. The invention explores the change of the expression profile of the bioactive small molecules after the response to the exercise, further finds out the enzymatic reaction of related metabolic pathways, finds out the action mechanism of the small molecules generated by the exercise stimulation, and further carries out verification and evaluation on the curative effect of the small molecules as myocardial infarction drugs. The invention has important value for the treatment and prevention of myocardial infarction patients.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical preparations used for treatment of acute and chronic diseases or urinary ways (pyelonephritis, urethritis, cystitis, prostatitis and others). Uroantiseptic agent comprises pipemidinic acid as an active component and lactose, stearic acid or its salts and aerosil as special accessory components. Pipemidinic acid can be presented as trihydrate. Invention provides the high technological effectiveness of preparing this drug, guaranteed decomposition and rapid release of drugs from the composition using available components. EFFECT: improved properties, enhanced effectiveness of agent. 4 cl, 1 ex
This study was aimed to investigate the relationship between isokinetic muscle strength of shoulder internal and external rotation, grip strength, anaerobic capacity, aerobic capacity and sportive performance in wheelchair basketball athletes.

26 wheelchair basketball athletes were involved into the study. Wheelchair basketball players were divided into two groups according to the classification levels (Group 1: less than 3 points, Group 2: 3 points and higher). Upper extremity muscle strengths were evaluated with the ISOMED 2000® isokinetic device. Hand grip strength was evaluated with hydraulic hand dynamometer. The measurement of the aerobic capacity was measured using its own wheelchair on the treadmill by applying a custom ramp protocol. Anaerobic capacity was evaluated with Wingate anaerobic power test (WAnT) for 30 seconds in standard laboratory conditions. The sportive performances were assessed by "20 m Sprint test", "Slalom Test" and "Zone Shot" tests.
Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to cosmetics, particularly antiperspirants. An "water-in-oil" emulsion composition of a solid astringent stick contains an antiperspirant salt 34 wt % to 70 wt %, a dispersed water phase containing 15 to 30 wt % of water-soluble astringent antiperspirant aluminium-zirconium salts, 29 wt % to 65 wt % of an oil phase containing at least one oil and hydrocarbon wax which hardens oil; hydrocarbon wax contains at least 1 portion wt/wt of polyethylene of intermediate molecular weight representing average molecular weight making 360 to 460 Da per 8 portions of the oil phase, and 0.125 wt % to 2.0 wt % of a silicone emulsifier. A method for producing the composition and application shows weak or improved braking and weak or improved visible traces. A non-therapeutic method of local sweating inhibition or regulation is provided by rubbing-in, preferentially in an axillary crease. ^ EFFECT: invention provides the required aesthetic characteristics including weak braking and good sliding and subtle traces with preferable hardness of the stick. ^ 26 cl, 11 tbl, 48 ex
This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
Hyperglucagonemia contributes significantly to the hyperglycemia characterizing patients with Type 2 diabetes. Fasting hyperglucagonemia induces hepatic glucose release resulting in elevated fasting levels of plasma glucose. Furthermore, lack of postprandial suppression of glucagon secretion - exchanged for a paradoxical postprandial hypersecretion of glucagon - results in increased levels of postprandial plasma glucose. Additionally, type 2 diabetes is characterized by decreased postprandial responses of the insulinotropic (and glucagonostatic) peptide hormone glucagon-like peptide-1 (GLP-1). Recent studies from our group suggest that the intestines are involved in the diminshed suppression of glucagon following ingestion of nutrients. Thus, suppression of glucagon during oral glucose ingestion diminishes and reverses to stimulation while suppression during intravenous administered glucose sustains along with development of glucose intolerance. In the small intestines mucosal endocrine L-cells secrete GLP-1, which is processed from its precursor, proglucagon, by prohormone convertase 1 (PC1). In the pancreatic alpha-cells proglucagon is processed to glucagon via prohormone convertase 2 (PC2). We plan to examine biopsies from the mucosa of the small intestines from patients with type 2 diabetes and from healthy subjects for glucagon production. Furthermore, the volunteers will be subjected to a standard meal test in order to correlate the gene expression studies with the level of postprandial hyperglucagonemia of the subjects.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having strong α-glucosidase inhibitory activity, being readily taken by making the inhibitor include a spice as an active ingredient. SOLUTION: This inhibitor contains a spice as an active ingredient. For example, oregano, peppermint, rosemary, basil, etc., may be cited as the kind of spice. Though the spice is used in an ordinary state, further dried and powdered or ground in water into a slurried state and the slurried spice may show glucosidase inhibitory activity, an extract obtained by using water and/or an alcohol preferably provides stronger α-glucosidase inhibitory activity. An extract obtained by using a mixed solution of water and an alcohol is especially preferable. Methanol, ethanol, propanol, butanol, etc., may be cited as the alcohol and ethanol is preferable. The weight ratio of water/the alcohol is preferably 1/100 to 100/1.
Endovascular aortic repair (EVAR) is nowadays the establishment treatment for patients with abdominal aortic aneurysm (AAA) both in elective and urgent setting. Despite the large applicability and satisfactory results, the presence of hostile iliac anatomy affects both technical and clinical success. This narrative review aimed to report the impact of iliac access and related adjunctive procedures in patients undergoing EVAR in elective and non-elective setting. Hostile iliac access can be defined in presence of narrowed, tortuous, calcified, or occluded iliac arteries. These iliac characteristics can be graded by the anatomic severity grade score to quantitatively assess anatomic complexity before undergoing treatment. Literature shows that iliac hostility has an impact on device navigability, insertion and perioperative and postoperative results. Overall, it has been correlated to higher rate of access issues, representing up to 30% of the first published EVAR experience. Recent innovations with low-profile endografts have reduced large-bore sheaths related issues. However, iliac-related complications still represent an issue, and several adjunctive endovascular and surgical strategies are nowadays available to overcome these complications during EVAR. In urgent settings iliac hostility can significantly impact on particular time sensitive procedures. Moreover, in case of severe hostility patients might be written off for EVAR repair might be inapplicable, exposing to higher mortality/morbidity risk in this urgent/emergent setting. In conclusion, an accurate anatomical evaluation of iliac arteries during preoperative planning, materials availability, and skilled preparation to face iliac-related issues are crucial to address these challenges.
Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. PERCOCET is not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including PERCOCET, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression.
At the beginning of the study, standard diabetes education will be given, and they will be asked to fill out the Children with Type 1 Diabetes Information Form, the Quality of Life Scale for Children with Type 1 Diabetes, and the Diabetes Management Self-Efficacy Scale. All scales will be administered again in the 12th and 15th weeks from the beginning of the study.
Childhood cancer patients and their parents are faced with significant stress at the time of diagnosis, during treatment, and over the course of recovery. The stress of cancer and its treatment can lead to significant emotional distress for many families. However, most families do not have access to programs that offer support for coping with cancer-related stress. The proposed work will address this gap by testing of the possible benefits of a novel internet delivered program to support children with cancer and their parents in coping with and communicating about a child's cancer. This online program includes modules to teach parenting, communication and coping skills to parents of children with cancer, and coping skills to their children who have been recently diagnosed with cancer. The research team includes experts from Vanderbilt University and Nationwide Children's Hospital with experience in pediatric oncology; stress, coping, and family communication in pediatric cancer; internet interventions in pediatric populations; and family-focused interventions to build coping and parenting skills. The study will test the effects of this program in 150 families of children with newly diagnosed cancer on reducing emotional distress up to 12 months after participation in the program. This project has the potential to lead to an evidence-based program to improve quality of life and resilience in children with cancer and their parents that can be easily and widely disseminated.
Kawasaki disease (KD), which is also known as cutaneous mucosal lymph node syndrome, is an acute, self-limiting, necrotizing vasculitis with unclear cause that primarily affects small- and medium-sized blood vessels and most commonly affects children aged 6 months to 5 years. Currently, diagnosis is based primarily on typical clinical symptoms. Approximately 15%-20% of patients are highly suspected of having KD; however, they do not match the diagnostic criteria for typical KD, which is referred to as incomplete Kawasaki disease (IKD), and this has become a major challenge in the diagnosis and treatment of KD. We describe a case of a 7-year-old boy who had a fever and jaundice as his initial symptoms. After a series of clinical laboratory and imaging examinations and marked improvement of symptoms after treatment with intravenous immunoglobulin (IVIG), IKD was considered as the diagnosis. When children present with jaundice and fever, physicians should consider KD as a possible diagnosis to ensure early detection and treatment of the disease.
Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Each one-second spray contains an average of 200 mg of product, not including propellant.

To apply, insert the cannula firmly onto the protruding plastic stem on the bottle and press the cannula forward to actuate the spray valve. The cannula may be removed and reinserted as many times as required for cleaning, or sterilization, and is autoclavable.
The present invention relates to an ointment for treating hemorrhoid complicated by anal fistula and a preparation method thereof. The ointment comprises arnebia root, phellodendron, coptis, scutellaria root, giant knotweed rhizome, liquorice, sanguisorba root, boneol and a proper amount of soybean oil. When in manufacture, the components are respectively heated in strong fire and stable fire, and are uniformly stirred to a paste form and canned. The ointment sufficiently absorbs the advantage of the traditional Chinese medicine theory, and can directly act on the nidus of a patient. The present invention has the advantages of convenient use, significant curative effect, high cure rate and no toxic side effect. The present invention can be used for fundamentally eradicating various hemorrhoid complicated by anal fistula diseases, and the pain of patients is reduced up to the hilt.
This research study is a pilot test of the effectiveness of a near infrared fluorescence imaging (NIFI) system in the detection and diagnosis of pulmonary nodules. Patients selected for enrollment in this study will be adults (≥18 years) that have been scheduled for surgical biopsy and/or resection of a primary lung nodule identified by prior imaging. Patients will receive an injection of indocyanine green (ICG) contrast dye one day prior to their surgery. Intraoperatively, the NIFI system will be used to visualize and characterize the fluorescence patterns given off by these lung nodules, as well as look for additional undiagnosed nodules. These nodules will then be resected and receive histological characterization, as per standard of care. The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules.
Monitor patients closely for hypersensitivity reactions, especially during the first and second infusions. Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. Severe hypersensitivity reactions require immediate discontinuation of the DOCIVYX infusion and aggressive therapy. Do not rechallenge patients with a history of severe hypersensitivity reactions with DOCIVYX [see Contraindications (4)].

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. Monitor patients with a previous history of hypersensitivity to paclitaxel closely during initiation of DOCIVYX therapy. Hypersensitivity reactions may occur within a few minutes following initiation of a DOCIVYX infusion. If minor reactions such as flushing or localized skin reactions occur, interruption of therapy is not required. All patients should be premedicated with an oral corticosteroid prior to the initiation of the infusion of DOCIVYX [see Dosage and Administration (2.6)].
PURPOSE:To obtain an anti-inflammatory agent having stability of an active ingredient higher than that of a conventional anti-inflammatory agent blended with astaxanthin, being expected to have higher effect, capable of lightening adverse effect of other anti-inflammatory agents and medicine components. CONSTITUTION:An anti-inflammatory agent comprises a diester of astaxanthin, preferably a fatty acid diester or a glycerophosphoric acid diester of astaxanthin. The diesters are extracted from a krill. When the diesters are identified by using a high-performance liquid chromatography, a column of RPC Microbondapach NH2 made of Waters Inc. (deltamm. i. dX-10mm) is used and n-hexane:2-propanolmethanol=75:15 is used for a mobile phase. In the case of making the diester flow at 2m/minute flow rate and observing absorption at 470nm by an ultraviolet light and visible light absorption spectrum detector, the diesters having a retention time providing the maximum peak in the range of 0.5-2.5 minute are preferable. When the diesters are blended with an aspirin preparation, adverse effects are lightened and an aspirin acid agent having increased effect can be obtained.
Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80° C. to produce a first mixture. A gelling agent and water is also provided and heat to at least 80° C. to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112° C. to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90° C. for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product. Furthermore, the present disclosure comprises a therapeutic comestible gummie product comprising ibuprofen and/or other active drug(s).
In addition to the adverse reactions reported during clinical trials, the following adverse experiences have been reported during clinical practice in patients treated with ceftriaxone for injection. Data are generally insufficient to allow an estimate of incidence or to establish causation.

A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both cefrtiaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone for injection and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates.
Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
Venlafaxine extended-release tablets are indicated for the treatment of Social Anxiety Disorder (SAD), also known as Social Phobia, as defined in DSM-IV. 

Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning or social activities or relationships or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. 

Efficacy of venlafaxine extended-release in the treatment of SAD was established in short-term SAD trials [see Clinical Studies (14.2)].